These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 38384647)

  • 1. Immune Evasion Through Human Leukocyte Antigen Implications and Its Impact on Targeted Therapy.
    Andreescu M; Andreescu B
    Cureus; 2024 Jan; 16(1):e52737. PubMed ID: 38384647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Impact of Human Leukocyte Antigen-Type and Cytokine-Type Responses on Outcomes after Targeted Therapy Currently Used to Treat Chronic Lymphocytic Leukemia.
    Andreescu M; Berbec N; Tanase AD
    J Clin Med; 2023 Apr; 12(7):. PubMed ID: 37048814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Leukocyte Antigen-G (HLA-G) Expression in Cancers: Roles in Immune Evasion, Metastasis and Target for Therapy.
    Lin A; Yan WH
    Mol Med; 2015 Nov; 21(1):782-791. PubMed ID: 26322846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies.
    Seliger B
    HLA; 2016 Nov; 88(5):213-220. PubMed ID: 27659281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors.
    Jan CI; Huang SW; Canoll P; Bruce JN; Lin YC; Pan CM; Lu HM; Chiu SC; Cho DY
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activation.
    Rodríguez JA
    Oncol Lett; 2017 Oct; 14(4):4415-4427. PubMed ID: 29085437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA Class I Downregulation by HIV-1 Variants from Subtype C Transmission Pairs.
    Ende Z; Deymier MJ; Claiborne DT; Prince JL; Mónaco DC; Kilembe W; Allen SA; Hunter E
    J Virol; 2018 Apr; 92(7):. PubMed ID: 29321314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Host KIR/HLA-C Genotypes Determine HIV-Mediated Changes of the NK Cell Repertoire and Are Associated With Vpu Sequence Variations Impacting Downmodulation of HLA-C.
    Vollmers S; Lobermeyer A; Niehrs A; Fittje P; Indenbirken D; Nakel J; Virdi S; Brias S; Trenkner T; Sauer G; Peine S; Behrens GMN; Lehmann C; Meurer A; Pauli R; Postel N; Roider J; Scholten S; Spinner CD; Stephan C; Wolf E; Wyen C; Richert L; Norman PJ; Sauter J; Schmidt AH; Hoelzemer A; Altfeld M; Körner C
    Front Immunol; 2022; 13():922252. PubMed ID: 35911762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Individual HLA heterogeneity and its implications for cellular immune evasion in cancer and beyond.
    Pagliuca S; Gurnari C; Rubio MT; Visconte V; Lenz TL
    Front Immunol; 2022; 13():944872. PubMed ID: 36131910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion.
    Morton LT; Wachsmann TLA; Meeuwsen MH; Wouters AK; Remst DFG; van Loenen MM; Falkenburg JHF; Heemskerk MHM
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection of an HLA-C*03:04-Restricted HIV-1 p24 Gag Sequence Variant Is Associated with Viral Escape from KIR2DL3+ Natural Killer Cells: Data from an Observational Cohort in South Africa.
    Hölzemer A; Thobakgale CF; Jimenez Cruz CA; Garcia-Beltran WF; Carlson JM; van Teijlingen NH; Mann JK; Jaggernath M; Kang SG; Körner C; Chung AW; Schafer JL; Evans DT; Alter G; Walker BD; Goulder PJ; Carrington M; Hartmann P; Pertel T; Zhou R; Ndung'u T; Altfeld M
    PLoS Med; 2015 Nov; 12(11):e1001900; discussion e1001900. PubMed ID: 26575988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defective Influenza A Virus RNA Products Mediate MAVS-Dependent Upregulation of Human Leukocyte Antigen Class I Proteins.
    Rahim MMA; Parsons BD; Price EL; Slaine PD; Chilvers BL; Seaton GS; Wight A; Medina-Luna D; Dey S; Grandy SL; Anderson LE; Zamorano Cuervo N; Grandvaux N; Gaglia MM; Kelvin AA; Khaperskyy DA; McCormick C; Makrigiannis AP
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32321802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA-G and its KIR ligands in cancer--another enigma yet to be solved?
    Urosevic M; Trojan A; Dummer R
    J Pathol; 2002 Mar; 196(3):252-3. PubMed ID: 11857486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying the immune interactions underlying HLA class I disease associations.
    Debebe BJ; Boelen L; Lee JC; ; Thio CL; Astemborski J; Kirk G; Khakoo SI; Donfield SM; Goedert JJ; Asquith B
    Elife; 2020 Apr; 9():. PubMed ID: 32238263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human leukocyte antigen-G expression and polymorphisms promote cancer development and guide cancer diagnosis/treatment.
    Zhang Y; Yu S; Han Y; Wang Y; Sun Y
    Oncol Lett; 2018 Jan; 15(1):699-709. PubMed ID: 29399142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune evasion by cancer stem cells.
    Tsuchiya H; Shiota G
    Regen Ther; 2021 Jun; 17():20-33. PubMed ID: 33778133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune response and evasion mechanisms in lip carcinogenesis: An immunohistochemical study.
    Lopes MLDS; Gonzaga AKG; Mosconi C; Palomino GM; Mendonça EF; Batista AC; Silveira ÉJDD
    Arch Oral Biol; 2019 Feb; 98():99-107. PubMed ID: 30468994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of immune checkpoints in antitumor response: a potential antitumor immunotherapy.
    Mejía-Guarnizo LV; Monroy-Camacho PS; Turizo-Smith AD; Rodríguez-García JA
    Front Immunol; 2023; 14():1298571. PubMed ID: 38162657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.
    Imai D; Yoshizumi T; Okano S; Uchiyama H; Ikegami T; Harimoto N; Itoh S; Soejima Y; Aishima S; Oda Y; Maehara Y
    Cancer Med; 2017 Jul; 6(7):1614-1626. PubMed ID: 28602029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defective HLA Class I Expression and Patterns of Lymphocyte Infiltration in Chordoma Tumors.
    Patel SS; Nota SP; Sabbatino F; Nielsen GP; Deshpande V; Wang X; Ferrone S; Schwab JH
    Clin Orthop Relat Res; 2021 Jun; 479(6):1373-1382. PubMed ID: 33273248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.